01:20 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Poisoning Cell culture studies suggest inhibiting CYPR, SLC45A4 or ATP7A could help treat paraquat poisoning. Screening of a CRISPR single-guide RNA (sgRNA) library targeting metabolism-related genes in a paraquat-treated human T cell line expressing CRISPR-associated...
07:00 , Sep 24, 2015 |  BC Innovations  |  Tools & Techniques

Poppy-free opiates

A new system for synthesizing opioids in yeast offers the first realistic chance of producing the painkillers without relying on poppy field farming, and represents the most sophisticated biosynthetic pathway engineered in yeast to date....
07:00 , Mar 12, 2007 |  BC Week In Review  |  Company News

CXR, Millipore sales and marketing update

MIL and co-development partner CXR launched collections of anti-bodies that identify human enzymes and trancription factors involved in drug metabolism and regulation. The antibodies recognize cytochrome P450 2D6 (CYP2D6), cytochrome P450 2A6 (CYP2A6);...
07:00 , Jun 28, 2004 |  BioCentury  |  Politics, Policy & Law

What's in a model?

Drug development relies heavily on animal models to validate targets, to anticipate the effect of a drug on a target of interest, and to assess potential side effects. Yet despite the fact that creating good...
08:00 , Mar 24, 2003 |  BC Week In Review  |  Company News

CXR, Pfizer deal

Pfizer Ltd. (Sandwich, U.K.), the U.K. unit of PFE, received non-exclusive access to the HRN mouse technology from CXR. HRN technology uses a transgenic mouse strain with conditional deletion of the cytochrome P450 reductase...
08:00 , Mar 19, 2003 |  BC Extra  |  Company News

Pfizer, CXR technology deal

Pfizer (Sandwich, U.K.), the U.K. unit of Pfizer (PFE), received a non-exclusive license to access the HRN mouse technology from CXR Biosciences (Dundee, U.K.). The HRN technology uses a transgenic mouse strain with conditional deletion...
08:00 , Mar 10, 1999 |  BC Week In Review  |  Company News

Cypros other research news

CYPR received a $100,000 SBIR grant from the National Institute of Neurological Disorders and Stroke to develop glial chloride channel blockers. The blockers may reduce the swelling of glial cells to protect the brain from...
08:00 , Dec 8, 1997 |  BC Week In Review  |  Company News

Cypros, Enquay Inc. deal

CYPR acquired from Enquay two controlled release topical wound care drugs, Sildimac and Medimac, for an undisclosed amount. Sildimac contains silver sulfadiazine, a topical antimicrobial to treat burns. Medimac contains the active ingredients found in...
08:00 , Dec 8, 1997 |  BC Week In Review  |  Company News

Cypros management update

Cypros Pharmaceutical Corp. (CYPR), Carlsbad, Calif.   Business: Cardiovascular, Neurological   Hired: Zofia Dziewanowska as SVP of clinical development and regulatory affairs, fomerly VP and head of clinical research at Hoffmann-La Roche   ...
07:00 , Oct 20, 1997 |  BC Week In Review  |  Clinical News

CPC-111 fructose-1 data

CYPR announced positive results from its double-blind Phase II trial of CPC-111 to reduce pain associated with sickle cell anemia crisis. A total of 47 patients were given single intravenous infusions of placebo or 50,...